Quantcast
Last updated on April 18, 2014 at 15:51 EDT

Latest cell therapy Stories

2013-12-18 09:49:54

A systematic survey of the scientific literature shows that stem cell therapy can have a statistically significant impact on animal models of spinal cord injury, and points the way for future studies. Spinal cord injuries are mostly caused by trauma, often incurred in road traffic or sporting incidents, often with devastating and irreversible consequences, and unfortunately having a relatively high prevalence (250,000 patients in the USA; 80% of cases are male). High-profile campaigners...

2013-12-17 23:24:06

The charitable nonprofit Let's Cure CP (http://www.CureCP.org) is the only parent led advocacy group for Cerebral Palsy families whose sole purpose is to raise funds for research. (PRWEB) December 17, 2013 As one of the primary fund-raisers and promoters of this trial, CureCP.org is an honored collaborator and is very proud to announce that the first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy (CP) has begun at The University...

2013-12-17 08:30:02

New patient reviews allows public insight into stem cell therapy through StemGenex LA JOLLA, Calif., Dec. 17, 2013 /PRNewswire/ -- StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the public release of their satisfaction ratings for patients who have received stem cell therapy through StemGenex. http://photos.prnewswire.com/prnvar/20131217/LA31464 Patients...

2013-12-16 04:21:51

ALBANY, New York, December 16, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research, "Cord Blood Banking Services Market (Private and Public Cord Blood Banks) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global cord blood banking services market was valued at USD 12.40 billion in 2012 and is expected to grow at a CAGR of 5.6% from 2013 to 2019, to reach an estimated value of USD 15.23 billion...

2013-12-13 16:24:24

PALO ALTO, Calif., Dec. 13, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. The...

2013-12-11 12:25:22

MONT-SAINT-GUIBERT, Belgium, December 11, 2013 /PRNewswire/ -- Study Demonstrates Enhanced Endomyocardial Therapeutics Retention through an Optimized Delivery System Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces the advanced publication of C-Cath(R)...

2013-12-09 23:22:07

Generating new cardiac muscle from human embryonic stem cells (hESCs) and/or induced pluripotent stem cells (iPSC) could fulfill the demand for therapeutic applications and drug testing. The production of a similar population of these cells remains a major limitation, but in a study just published in STEM CELLS Translational Medicine, researchers now believe they have found a way to do this. Durham, NC (PRWEB) December 09, 2013 Generating new cardiac muscle from human embryonic stem cells...

2013-12-09 10:12:57

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. Today, many patients with newly diagnosed blood disorders – ranging from cancer to rare genetic conditions – respond well to modern treatment regimens. However, for...

2013-12-09 08:27:03

Discosphere(TM) Discogenic Stem-Like Progenitor Cells Hold Potential to Regenerate New Intervertebral Disc Material for Millions of Patients BOTHELL, Wash., Dec. 9, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that Discgenics, Inc., a privately-held Salt Lake...

Genetically Modified Cells Produce Long-term Remissions
2013-12-09 06:46:50

University of Pennsylvania School of Medicine Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to...